Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 1;11:2475–2487. doi: 10.2147/OTT.S160192

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Liu et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

UCA1 knockdown hampered proliferation and invasion and induced apoptosis in RCC cells.

Notes: 786O and ACHN cells were transfected with siRNAs targeting UCA1 (siUCA1-1 and siUCA1-2) and its scrambled control (siCon), followed by the detection of UCA1 expression at 48 hours posttransfection (A); assessment of proliferation ability after transfection at the time points indicated (B); evaluation of invasive capacity at 48 hours following siRNA treatment, magnification: 200× (C); measurement of apoptosis rate at 48 hours following siRNA treatment (D). *P<0.05.

Abbreviations: RCC, renal cell carcinoma; PI, propidium iodide; FITC, fluorescein isothiocyanate.

UCA1 knockdown hampered proliferation and invasion and induced apoptosis in RCC cells.

Notes: 786O and ACHN cells were transfected with siRNAs targeting UCA1 (siUCA1-1 and siUCA1-2) and its scrambled control (siCon), followed by the detection of UCA1 expression at 48 hours posttransfection (A); assessment of proliferation ability after transfection at the time points indicated (B); evaluation of invasive capacity at 48 hours following siRNA treatment, magnification: 200× (C); measurement of apoptosis rate at 48 hours following siRNA treatment (D). *P<0.05.

Abbreviations: RCC, renal cell carcinoma; PI, propidium iodide; FITC, fluorescein isothiocyanate.